Cargando…

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?

BACKGROUND: Treatment-resistant schizophrenia (TRS) may underlie a specific biological signature among patients with schizophrenia. The main lines of evidence suggest a glutamatergic rather than dopaminergic dysfunction in TRS, with lower levels of striatal dopamine and higher levels of glutamate in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertolucci, Bruno, Pitta, José Cássio, Higuchi, Cinthia, Noto, Cristiano, Rocha, Deyvis, Joyce, Dan, Correll, Christoph, Bressan, Rodrigo, Gadelha, Ary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888556/ http://dx.doi.org/10.1093/schbul/sby018.916

Ejemplares similares

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA
por: Loures Malinowski, Fernando Rocha, et al.
Publicado: (2018)

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA
por: Oliveira, Hianna, et al.
Publicado: (2018)

F91. ASSOCIATION BETWEEN SYMPTOM DIMENSIONS AND EXECUTIVE FUNCTION IN SCHIZOPHRENIA
por: Franco, Ana Luiza, et al.
Publicado: (2018)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Assunção-Leme, Idaiane, et al.
Publicado: (2018)

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)
por: Coutinho, Luccas, et al.
Publicado: (2018)

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA
por: Elias, Beatriz Yukie, et al.
Publicado: (2018)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review
por: Haguiara, Bernardo, et al.
Publicado: (2021)

Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis
por: Malinowski, Fernando R., et al.
Publicado: (2019)

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia
por: Pinaya, Walter H. L., et al.
Publicado: (2016)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

COVID-19 contamination and severity among patients with schizophrenia: Results from a specialized outpatient clinic survey
por: Costardi, Carlos Gustavo, et al.
Publicado: (2022)

M184. SOCIAL SKILLS TRAINING FOR TREATMENT-RESISTANT SCHIZOPHRENIA WITH PREDOMINANTLY NEGATIVE SYMPTOMS
por: Kayo, Monica, et al.
Publicado: (2020)

How challenging is to manage agitated patients?
por: Cavalcante, Daniel A., et al.
Publicado: (2019)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

Clozapine prescription trends in Brazil in the last decade
por: Massuda, Raffael, et al.
Publicado: (2022)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

Component mechanisms of executive function in schizophrenia and their contribution to functional outcomes
por: Berberian, Arthur A., et al.
Publicado: (2018)

A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
por: Nani, João V, et al.
Publicado: (2020)

S24. PATHWAYS LINKING ENVIRONMENTAL RISKS, POLYGENIC RISK SCORE TO SCHIZOPHRENIA AND PSYCHOTIC EXPERIENCES IN A BRAZILIAN COHORT OF CHILDREN AND ADOLESCENTS
por: Fonseca, Lais, et al.
Publicado: (2020)

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data
por: Gouvêa, Eduardo S., et al.
Publicado: (2017)

PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia
por: Ota, Vanessa K., et al.
Publicado: (2014)

T126. PSYCHOTIC EXPERIENCES AND COMMON MENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE: BIDIRECTIONAL AND TRANSDIAGNOSTIC ASSOCIATIONS IN A LONGITUDINAL COMMUNITY-BASED STUDY
por: Pan, Pedro, et al.
Publicado: (2018)

Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families
por: Gadelha, Ary, et al.
Publicado: (2012)

Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia?
por: Berberian, Arthur A., et al.
Publicado: (2016)

Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages
por: Ota, Vanessa Kiyomi, et al.
Publicado: (2019)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

O12.8. LOWER FAMILY INCOME PREDICTS PSYCHOTIC EXPERIENCES IN A COMMUNITY SAMPLE OF YOUTHS IN BRAZIL: RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
por: Fonseca, Lais, et al.
Publicado: (2018)

Schizophrenia and COVID-19: risks and recommendations
por: Fonseca, Lais, et al.
Publicado: (2020)

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls
por: Matsuzaka, Camila T., et al.
Publicado: (2017)

T125. INCIDENCE OF TREATMENT RESISTANCE SCHIZOPHRENIA IN A COMMUNITY SAMPLE USING THE TRRIP CONCENSUS
por: Joyce, Dan, et al.
Publicado: (2018)

Hair cortisol in drug-naïve first-episode individuals with psychosis
por: Andrade, Elvis H., et al.
Publicado: (2016)

Evaluating the effectiveness of a training program that builds teachers’ capability to identify and appropriately refer middle and high school students with mental health problems in Brazil: an exploratory study
por: Vieira, Marlene A, et al.
Publicado: (2014)

Systematic sequencing of mRNA from the Antarctic krill (Euphausia superba) and first tissue specific transcriptional signature
por: De Pittà, Cristiano, et al.
Publicado: (2008)

COVID-19 pandemic and distinct patterns of psychotic outbreaks
por: Costardi, Carlos Gustavo, et al.
Publicado: (2021)

Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
por: Correll, Christoph U., et al.
Publicado: (2023)

T159. STRUCTURAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA IN ADVERSE ENVIRONMENTS: EXAMINING THE EFFECT OF POVERTY AND VIOLENCE IN SIX LATIN AMERICAN CITIES
por: Crossley, Nicolas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_utfghd0p2ifvpdpko06so23fna